Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
setrobuvir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A: STV capsule (after high fat meal) | ACTIVE_COMPARATOR | - |
| B: STV capsule (fasted state) | ACTIVE_COMPARATOR | - |
| C: STV tablet (after high fat meal) | EXPERIMENTAL | - |
| D: STV tablet (fasted state) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| setrobuvir | DRUG | 200 mg capsule formulation, single oral dose |
Inclusion Criteria: * Healthy male and female adults, 18 to 55 years of age inclusive * Body mass index (BMI) 18.0 - 30.0 kg/m2 * Healthy status defined as absence of clinically significant acute or chronic condition as determined by complete medical history and physical examination * Females of ch...
Setrobuvir is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and remains in clinical development. The completed Phase 1 trial evaluated the drug in healthy volunteer subjects to assess the relative bioavailability of different formulations.
Setrobuvir is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company sponsored a Phase 1 clinical trial of the drug in healthy volunteers.
Setrobuvir is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
Setrobuvir has one completed clinical trial, NCT01612143, titled "A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers." This Phase 1 study enrolled 40 participants in the Netherlands and was active-controlled.
No alternative names for setrobuvir have been reported. The drug is known only by the name setrobuvir in clinical development records.